Pembrolizumab和nivolumab治療復發性／轉移性子宮頸癌的檢視

The role of pembrolizumab and nivolumab in the management of recurrent/metastatic cervical cancer

雖然合併許多治療的方法，對復發性／轉移性的子宮頸癌病灶有效，臨床上仍需尋找更有效的方式，免疫治療乃其中一種新的治療方法。免疫檢查抑制劑（pembroizumab和nivolumab）是最近在研究藥物，能延長復發性／轉移性病灶的子宮頸癌患者性命。2018年，美國食品藥物管理局已通過pembrolizumab作為第二線治療復發性／轉移性病灶的子宮頸癌；2021年又通過pembrolizumab可以合併使用化學藥物，和同時使用或不使用bevacizumab，來治療病灶有PD-L1顯示的持續性、轉移性或復發性的子宮頸癌。最近較新的報告亦認為，nivolumab對復發性／轉移性病灶的子宮頸癌，治療效果十分良好。

Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcomes in treating recurrent/ metastatic cervical cancer. Immunotherapy is emerging as a novel therapeutic approach in this disease. Immune checkpoint inhibitors (pembrolizumab and nivolumab) have recently emerged as novel therapeutic pillars that could provide durable responses with impact on overall survival in patients in the recurrent/metastatic cervical cancer. In 2018, pembrolizumab was approved by FDA (Food and Drug Administrated) for the second-line treatment of recurrent/metastatic cervical cancer. In 2021, pembrolizumab was approved by FDA for use in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. In addition, the efficacy of nivolumab in patients with recurrent/metastatic cervical cancer is promising in recent reports.